ExampleResearch writingMedicine & healthcare

Example methodology chapter: systematic review protocol for emerging cancer therapies (annotated)

An annotated model methodology chapter that sets out a systematic review protocol on immune checkpoint inhibitors in advanced solid tumours. It helps PhD scholars in health sciences write a complete, registrable review protocol.

What you will learn

  • Narrow a broad clinical topic into an answerable review question
  • Describe a registered, reproducible search strategy
  • Choose risk-of-bias tools that match the included study designs
  • Pre-specify effect measures, pooling rules and heterogeneity assessment
  • Plan how the certainty of evidence will be graded and reported

What you will unlearn

  • A systematic review can cover all emerging therapies.A protocol needs a focused question that reviewers can apply consistently.
  • "The Cochrane tool" is a sufficient description.Name the tool: RoB 2 for randomised trials, ROBINS-I for non-randomised studies of interventions.
  • Ethics sections are not needed for reviews.Reviews still need statements on approval, data sharing, conflicts and complete reporting.
  • Any source with a DOI is reliable.Check that the DOI matches the citation and that the publisher is reputable.

Skills you will practise

  • Review question (PICO)
  • Search strategy
  • Risk of bias
  • Meta-analysis planning
  • GRADE
  • Protocol registration

About this example

This page is an example methodology chapter for a doctoral thesis built around a systematic review and meta-analysis in oncology. In a review-based thesis, the methodology chapter is essentially the review protocol: it fixes the question, the search, the selection rules, the risk-of-bias assessment and the synthesis before any results are seen. The example shows what a complete protocol contains and why each element is there.

It is an illustrative teaching example, not a real student's work, and it reports no results. The clinical question is deliberately framed in general terms and should be refined with an oncology supervisor. Read each part, then the "What to notice" note beneath it. Do not submit any part of it as your own work; your university's academic integrity rules apply.

The example: review question and registration

3.1 Review design

This is a systematic review of intervention effects, with meta-analysis where studies are sufficiently similar (Grant & Booth, 2009). It will be reported according to PRISMA 2020 (Page et al., 2021) and was registered on PROSPERO before screening began; any changes to this protocol will be dated and explained in the thesis.

3.2 Review question

Table 3.1. Review question in PICO form.
ElementDefinition in this review
PopulationAdults (18 years or over) with advanced or metastatic solid tumours
InterventionImmune checkpoint inhibitors, alone or combined with other systemic therapy
ComparatorStandard systemic therapy without a checkpoint inhibitor, as defined in each trial
OutcomesPrimary: overall survival. Secondary: progression-free survival, grade 3 or higher adverse events, health-related quality of life
Study designsRandomised controlled trials; non-randomised studies only for long-term safety

The example: risk of bias and synthesis

3.5 Risk of bias

Randomised trials will be assessed with the revised Cochrane tool, RoB 2, for each primary and secondary outcome (Sterne et al., 2019). Non-randomised studies contributing safety data will be assessed with ROBINS-I (Sterne et al., 2016). Assessments will be made independently by two reviewers.

3.6 Synthesis

Overall and progression-free survival will be pooled as log hazard ratios, and adverse events as risk ratios (Higgins et al., 2019), using random-effects meta-analysis because clinical variation between trials is expected. Heterogeneity will be described with the I² statistic and its confidence interval (Higgins et al., 2003) and explored in pre-specified subgroups (tumour type, line of therapy, monotherapy or combination). Where studies are too different to pool, results will be tabulated and synthesised narratively by outcome. Sensitivity analyses will exclude trials at high risk of bias.

3.7 Certainty of evidence

The certainty of evidence for each main outcome will be graded with the GRADE approach and presented in summary of findings tables (Guyatt et al., 2013). For each outcome these tables will show the number of trials and participants, the pooled effect with its 95% confidence interval, the corresponding absolute effect where baseline risks allow, and the certainty rating with the reasons for any downgrading. Before submission, the completed review will be checked against AMSTAR 2 as a self-assessment of methodological quality (Shea et al., 2017).

Table 3.2. Summary of methodological choices.
Protocol elementChoice in this reviewWhy
Reporting guidelinePRISMA 2020Complete, comparable reporting (Page et al., 2021)
RegistrationPROSPERO, before screeningProtects against changing methods after seeing data
Bias tool, trialsRoB 2Outcome-level assessment of randomised trials (Sterne et al., 2019)
Bias tool, non-randomisedROBINS-IAssesses confounding and selection (Sterne et al., 2016)
Effect measuresHazard ratio; risk ratioSuit time-to-event and binary outcomes (Higgins et al., 2019)
CertaintyGRADETransparent judgement of confidence (Guyatt et al., 2013)

3.8 Ethics and dissemination

The review uses published and registry data only and involves no new participants, so formal ethical approval is not required; confirmation will be sought from the university ethics committee. The extracted data and analysis code will be shared in a public repository on publication, reviewers will declare any conflicts of interest, and results will be reported whatever their direction.

3.9 Timeline

Table 3.3. Planned timeline for the review within the thesis.
MonthsStage
1 to 3Protocol development, piloting of search and forms, registration
4 to 8Searches, de-duplication, title and abstract screening
9 to 12Full-text screening, data extraction, risk-of-bias assessment
13 to 16Meta-analysis, subgroup and sensitivity analyses, GRADE
17 to 20Search update, writing and supervisor review

How to adapt this to your own study

  1. Narrow your topic to a question you can state in PICO (or a suitable alternative) form.
  2. Register the protocol before screening and note every later change.
  3. Search several databases, trial registries and grey literature, and put the full strategy in an appendix.
  4. Name a risk-of-bias tool for each study design you include.
  5. Pre-specify effect measures, the meta-analysis model, heterogeneity assessment and subgroups.
  6. Grade the certainty of evidence for each main outcome.
  7. Check your references: avoid predatory sources and confirm that every DOI matches its citation.

Common mistakes in this chapter

  • A title or question too broad to search systematically.
  • No reporting guideline or registration.
  • Naming "the Cochrane tool" without saying which one, or using one tool for every design.
  • Restricting to English-language, published studies without justification.
  • Promising a meta-analysis without saying when pooling is appropriate.
  • Generic ethics and dissemination statements.
  • Citing predatory or mismatched sources in the method itself.
How this methodology chapter meets common examiner expectations.
What examiners look forWhere this example does itCheck in your own draft
A focused, answerable questionTable 3.1Could two reviewers apply your criteria the same way?
Transparency and registration3.1Is your protocol registered and dated?
A comprehensive search3.3 and Appendix AHave you searched beyond one or two databases?
Appropriate appraisal tools3.5Does each design have the right tool?
Pre-specified synthesis3.6 and Table 3.2Are effect measures and pooling rules fixed in advance?
Certainty of evidence3.7Will you say how confident readers can be in each result?
Reliable sourcesReferences limited to verified methodological sourcesHave you checked every reference?

Key takeaways

Your next step

Want to apply this to your own study?

  1. 1Tell us your topic, data and deadline
  2. 2A subject mentor reviews your work with you
  3. 3You get a plan and a quote
Literature review

References

  1. Bramer, W. M., Rethlefsen, M. L., Kleijnen, J., & Franco, O. H. (2017). Optimal database combinations for literature searches in systematic reviews: A prospective exploratory study. Systematic Reviews, 6, Article 245. https://doi.org/10.1186/s13643-017-0644-y
  2. Chalmers, I., Bracken, M. B., Djulbegovic, B., Garattini, S., Grant, J., Gülmezoglu, A. M., Howells, D. W., Ioannidis, J. P. A., & Oliver, S. (2014). How to increase value and reduce waste when research priorities are set. The Lancet, 383(9912), 156–165. https://doi.org/10.1016/S0140-6736(13)62229-1
  3. Grant, M. J., & Booth, A. (2009). A typology of reviews: An analysis of 14 review types and associated methodologies. Health Information & Libraries Journal, 26(2), 91–108. https://doi.org/10.1111/j.1471-1842.2009.00848.x
  4. Guyatt, G. H., Oxman, A. D., Santesso, N., Helfand, M., Vist, G., Kunz, R., Brozek, J., Norris, S., Meerpohl, J., Djulbegovic, B., Alonso-Coello, P., Post, P. N., Busse, J. W., Glasziou, P., Christensen, R., & Schünemann, H. J. (2013). GRADE guidelines: 12. Preparing summary of findings tables: Binary outcomes. Journal of Clinical Epidemiology, 66(2), 158–172. https://doi.org/10.1016/j.jclinepi.2012.01.012
  5. Higgins, J. P. T., Li, T., & Deeks, J. J. (2019). Choosing effect measures and computing estimates of effect. In J. P. T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M. J. Page, & V. A. Welch (Eds.), Cochrane handbook for systematic reviews of interventions (2nd ed., pp. 143–176). Wiley. https://doi.org/10.1002/9781119536604.ch6
  6. Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557–560. https://doi.org/10.1136/bmj.327.7414.557
  7. Hopewell, S., McDonald, S., Clarke, M., & Egger, M. (2007). Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database of Systematic Reviews, (2), MR000010. https://doi.org/10.1002/14651858.MR000010.pub3
  8. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., . . . Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, Article n71. https://doi.org/10.1136/bmj.n71
  9. Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., et al. (2017). AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 358, j4008. https://doi.org/10.1136/bmj.j4008
  10. Stang, A. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 25(9), 603–605. https://doi.org/10.1007/s10654-010-9491-z
  11. Sterne, J. A. C., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., et al. (2016). ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355, i4919. https://doi.org/10.1136/bmj.i4919
  12. Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., et al. (2019). RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. https://doi.org/10.1136/bmj.l4898

How to cite this article

Choose your referencing style, then copy. Check your university's or journal's guide for local variations.

PhD Research Lab Academy. (2024, May 24). Example methodology chapter: systematic review protocol for emerging cancer therapies (annotated). PhD Research Lab. https://www.phdassistance.com/sample-work/emerging-cancer-therapies-review/

PhD Research Lab Academy. “Example Methodology Chapter: Systematic Review Protocol for Emerging Cancer Therapies (annotated).” PhD Research Lab, 24 May 2024, www.phdassistance.com/sample-work/emerging-cancer-therapies-review. Accessed [access date].

PhD Research Lab Academy (2024) Example methodology chapter: systematic review protocol for emerging cancer therapies (annotated). PhD Research Lab. Available at: https://www.phdassistance.com/sample-work/emerging-cancer-therapies-review/ (Accessed: [access date]).

PhD Research Lab Academy. “Example Methodology Chapter: Systematic Review Protocol for Emerging Cancer Therapies (annotated).” PhD Research Lab. May 24, 2024. https://www.phdassistance.com/sample-work/emerging-cancer-therapies-review.

PhD Research Lab Academy, ‘Example Methodology Chapter: Systematic Review Protocol for Emerging Cancer Therapies (annotated)’ (PhD Research Lab, 24 May 2024) <https://www.phdassistance.com/sample-work/emerging-cancer-therapies-review> accessed [access date].

PhD Research Lab Academy. Example methodology chapter: systematic review protocol for emerging cancer therapies (annotated) [Internet]. PhD Research Lab; 2024 May 24 [cited [access date]]. Available from: https://www.phdassistance.com/sample-work/emerging-cancer-therapies-review/

PhD Research Lab Academy, “Example methodology chapter: systematic review protocol for emerging cancer therapies (annotated),” PhD Research Lab, May 24, 2024. [Online]. Available: https://www.phdassistance.com/sample-work/emerging-cancer-therapies-review. [Accessed: [access date]].

@online{emerging_cancer_therapies_review_2024,
  author = {{PhD Research Lab Academy}},
  title = {{Example methodology chapter: systematic review protocol for emerging cancer therapies (annotated)}},
  organization = {PhD Research Lab},
  date = {2024-05-24},
  url = {https://www.phdassistance.com/sample-work/emerging-cancer-therapies-review},
  urldate = {[access date]}
}

This article is for learning. Use it to understand the method and cite the original sources above in your own work; do not copy or submit it as your own.

Example methodology chapterNeed help applying it to your study?
Literature review